Literature DB >> 9818757

SCH56592 treatment of murine invasive aspergillosis.

J R Graybill1, R Bocanegra, L K Najvar, M F Luther, D Loebenberg.   

Abstract

Mice were immunosuppressed using corticosteroids and infected with conidia of Aspergillus fumigatus. Beginning 1 day after infection, mice were treated orally either with Noble agar or with SCH56592 suspended in Noble agar, or intraperitoneally with amphotericin B. SCH56592 prolonged survival and reduced lung tissue counts of A. fumigatus, while amphotericin B had marginal benefit. SCH56592 merits further development for treatment of aspergillosis.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9818757     DOI： 10.1093/jac/42.4.539

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  17 in total

1.  Antifungal prophylaxis is effective against murine invasive pulmonary aspergillosis.

Authors:  Gunter Rieg; Brad Spellberg; Julie Schwartz; Yue Fu; John E Edwards; Donald C Sheppard; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 2.  Pharmacokinetic/pharmacodynamic profile of posaconazole.

Authors:  Yanjun Li; Ursula Theuretzbacher; Cornelius J Clancy; M Hong Nguyen; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

3.  Efficacy of SCH56592 in a rabbit model of invasive aspergillosis.

Authors:  W R Kirkpatrick; R K McAtee; A W Fothergill; D Loebenberg; M G Rinaldi; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Efficacy of 2-(3,4-dimethyl-2,5-dihydro-1h-pyrrole-2-yl)-1-methylethyl pentanoate in a murine model of invasive aspergillosis.

Authors:  Rajesh Dabur; S K Diwedi; V Yadav; V Mishra; Rambir Singh; H Singh; G L Sharma
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

5.  Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis.

Authors:  Alexander J Lepak; Karen Marchillo; Jaimie Vanhecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

6.  ASP2397 Is a Novel Natural Compound That Exhibits Rapid and Potent Fungicidal Activity against Aspergillus Species through a Specific Transporter.

Authors:  Ikuko Nakamura; Keisuke Ohsumi; Shinobu Takeda; Kiyomitsu Katsumata; Satoru Matsumoto; Souichiro Akamatsu; Hikaru Mitori; Toru Nakai
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

7.  In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida.

Authors:  A Cacciapuoti; D Loebenberg; E Corcoran; F Menzel; E L Moss; C Norris; M Michalski; K Raynor; J Halpern; C Mendrick; B Arnold; B Antonacci; R Parmegiani; T Yarosh-Tomaine; G H Miller; R S Hare
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

8.  Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.

Authors:  R Petraitiene; V Petraitis; A H Groll; T Sein; S Piscitelli; M Candelario; A Field-Ridley; N Avila; J Bacher; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

9.  Efficacy of posaconazole in a murine model of central nervous system aspergillosis.

Authors:  Jackie K Imai; Gaurav Singh; Karl V Clemons; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  Novel inhalational murine model of invasive pulmonary aspergillosis.

Authors:  Donald C Sheppard; Gunter Rieg; Lisa Y Chiang; Scott G Filler; John E Edwards; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.